The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01X | Other antineoplastic agents | |
| 4 | L01XX | Other antineoplastic agents | |
| 5 | L01XX05 | Hydroxycarbamide |
| Active Ingredient | Description | |
|---|---|---|
| Hydroxycarbamide |
One of the mechanisms by which hydroxycarbamide acts is the elevation of foetal haemoglobin (HbF) concentrations in sickle cell patients. In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| HYDREA Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| SIKLOS Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| XROMI Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
